<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="case-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">XVHX9GSy4KDDNLXsPHVzYdj</article-id>
      <article-id pub-id-type="other">00017</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2005000200017</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(05)08400217</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2005000200017</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Sildenafil melhora a fun&#231;&#227;o ventricular direita no receptor de transplante card&#237;aco</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Paez</surname>
            <given-names>Rodrigo Pereira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Araujo</surname>
            <given-names>Wesley Ferreira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hossne Jr</surname>
            <given-names>Nelson Americo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Neves</surname>
            <given-names>Ana Lucia</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vargas</surname>
            <given-names>Guilherme Flora</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aguiar</surname>
            <given-names>Luciano de Figueiredo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Branco</surname>
            <given-names>Jo&#227;o Nelson Rodrigues</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Catani</surname>
            <given-names>Roberto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Buffolo</surname>
            <given-names>Enio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Escola Paulista de Medicina </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>02</month>
        <year>2005</year>
      </pub-date>
      <volume>84</volume>
      <issue>2</issue>
      <fpage>176</fpage>
      <lpage>178</lpage>
      <history>
        <date date-type="received">
          <day>08</day>
          <month>11</month>
          <year>2003</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>03</month>
          <year>2004</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Relatamos caso de um paciente submetido a transplante card&#237;aco ortot&#243;pico, onde se utilizou um doador marginal pela piora cl&#237;nica do receptor, que apresentava choque cardiog&#234;nico por disfun&#231;&#227;o de ventr&#237;culo direito secund&#225;ria a hipertens&#227;o pulmonar associado &#224; vasoplegia. Obtivemos recupera&#231;&#227;o hemodin&#226;mica do paciente, com redu&#231;&#227;o da resist&#234;ncia vascular pulmonar, retirada de drogas vasoativas e recupera&#231;&#227;o da fun&#231;&#227;o do ventr&#237;culo direito ap&#243;s a introdu&#231;&#227;o de sildenafil.</p>
      </abstract>
      <pub-date publication-format="electronic" date-type="pub">
        <day>08</day>
        <month>03</month>
        <year>2005</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>RELATO DE CASO</bold>
    </p>
    <p>Sildenafil melhora a fun&#231;&#227;o ventricular direita no receptor de transplante card&#237;aco</p>
    <p>
      <bold>Rodrigo Pereira Paez; Wesley Ferreira Araujo; Nelson Americo Hossne Jr; Ana Lucia Neves; Guilherme Flora Vargas; Luciano de Figueiredo Aguiar; Jo&#227;o Nelson Rodrigues Branco; Roberto Catani; Enio Buffolo</bold>
    </p>
    <p> S&#227;o Paulo, SP</p>
    <p>Escola Paulista de Medicina - Universidade Federal de S&#227;o Paulo </p>
    <p>
      <xref ref-type="corresp" rid="end">Endere&#231;o para correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>Relatamos caso de um paciente submetido a transplante card&#237;aco ortot&#243;pico, onde se utilizou um doador marginal pela piora cl&#237;nica do receptor, que apresentava choque cardiog&#234;nico por disfun&#231;&#227;o de ventr&#237;culo direito secund&#225;ria a hipertens&#227;o pulmonar associado &#224; vasoplegia. Obtivemos recupera&#231;&#227;o hemodin&#226;mica do paciente, com redu&#231;&#227;o da resist&#234;ncia vascular pulmonar, retirada de drogas vasoativas e recupera&#231;&#227;o da fun&#231;&#227;o do ventr&#237;culo direito ap&#243;s a introdu&#231;&#227;o de sildenafil.</p>
    <p> O uso de &#243;xido n&#237;trico inalat&#243;rio reduz a press&#227;o de art&#233;ria pulmonar, aumentando a produ&#231;&#227;o de guanosina-3',5'- monofosfato cicl&#237;co (GMPc) nas c&#233;lulas musculares lisas do pulm&#227;o<sup>1</sup>. Inibidores espec&#237;ficos da GMPc fosfodiesterase (PDE5), que hidrolisam o GMPc no m&#250;sculo liso vascular, promovem vasodilata&#231;&#227;o pulmonar<sup>2-4</sup>. </p>
    <p>Sildenafil &#233; um inibidor espec&#237;fico da PDE5 e aumenta o efeito vasodilatador pulmonar do &#243;xido n&#237;trico inalat&#243;rio<sup>5-8</sup>, previne as crises de hipertens&#227;o pulmonar ap&#243;s a retirada do &#243;xido n&#237;trico em doentes com hipertens&#227;o pulmonar grave<sup>5,9</sup> e tem efeito vasodilatador pulmonar pr&#243;prio<sup>10,11 </sup>aumentando os n&#237;veis de GMPc<sup>12</sup>. </p>
    <p>Molina e cols.<sup>11</sup> relataram redu&#231;&#227;o de 20% da PAPS de um paciente com hipertens&#227;o pulmonar por lupus eritematoso sist&#234;mico, que apresentava press&#245;es pulmonares em n&#237;veis supra-sist&#234;micos com doses elevadas de sildenafil (1600mg ao dia), referindo boa tolerabilidade da medica&#231;&#227;o. </p>
    <p>Em um estudo experimental, Weimann e cols.<sup>10 </sup>mostraram que o efeito vasodilatador pulmonar do sildenafil &#233; dose-dependente e inicia-se 5min ap&#243;s sua administra&#231;&#227;o, atingindo efeito m&#225;ximo em 10min. </p>
    <p>Michelakis e cols.<sup>12</sup> mostraram que pacientes candidatos a transplante card&#237;aco com hipertens&#227;o pulmonar apresentaram diminui&#231;&#227;o da resist&#234;ncia vascular pulmonar mais proeminente com sildenafil isolado na dose de 75mg, do que com &#243;xido n&#237;trico inalat&#243;rio em 80 ppm, associado a um aumento expressivo nos n&#237;veis de GMPc. </p>
    <p>O uso de doador feminino em receptor masculino sabidamente tem mortalidade precoce maior (OR=1.11, p=0,3), assim como receptor aguardando em UTI com uso de drogas vasoativas (OR=2.51, p&lt;0.0001)<sup>13-15</sup>. </p>
    <p>Relatamos caso de um paciente submetido a transplante card&#237;aco ortot&#243;pico, onde se utilizou um doador marginal pela piora cl&#237;nica do receptor, que apresentava um choque cardiog&#234;nico por disfun&#231;&#227;o de ventr&#237;culo direito secund&#225;ria a hipertens&#227;o pulmonar associado &#224; vasoplegia. </p>
    <p>N&#227;o encontramos na literatura nacional o emprego de sildenafil para hipertens&#227;o pulmonar em p&#243;s-operat&#243;rio. O objetivo deste relato &#233; propor uma nova e segura maneira de tratar fal&#234;ncia ventricular direita secund&#225;ria &#224; hipertens&#227;o pulmonar no p&#243;s-operat&#243;rio de transplante card&#237;aco. </p>
    <p>
      <bold>Relato do Caso</bold>
    </p>
    <p>Paciente masculino de 33 anos, com miocardiopatia dilatada idiop&#225;tica, apresentando-se em tipo funcional IV (NYHA) h&#225; dois anos e internado em baixo d&#233;bito card&#237;aco em uso de catecolaminas (dobutamina 6,6 mcg/kg/min e dopamina 8mcg/kg/min). Nessa condi&#231;&#227;o, o paciente se apresentava hipotenso (press&#227;o arterial de 70x40mmhg), com hepatomegalia, congest&#227;o pulmonar (estertores bibasais) e com dispn&#233;ia leve em repouso. </p>
    <p>Foi submetido a transplante card&#237;aco ortot&#243;pico em 02/08/2003. Devido &#224; r&#225;pida piora cl&#237;nica foi utilizado um doador marginal: mulher, 60kg, parada card&#237;aca de 15min 3 dias antes, uso de dopamina 12mcg/kg/min, hipocinesia difusa leve ao ecocardiograma com fun&#231;&#227;o global preservada. </p>
    <p> O transplante foi realizado pela t&#233;cnica bicaval em 165min de circula&#231;&#227;o extracorp&#243;rea e 117min de an&#243;xia, sob hipotermia leve (32&#186;C) e uso de cardioplegia anter&#243;grada intermitente sangu&#237;nea. O paciente foi retirado de circula&#231;&#227;o extracorp&#243;rea ap&#243;s a terceira tentativa e levado &#224; UTI com isoproterenol 0,11 mcg/kg/min, milrinona 0,75 mcg/kg/min e dobutamina 20mcg/kg/min, com press&#227;o arterial m&#233;dia de 40mmHg, press&#227;o arterial pulmonar m&#233;dia de 45mmHg, com p&#233;ssima contratilidade do ventr&#237;culo direito e recebendo doses em bolus de adrenalina durante o transporte e nas primeiras horas de UTI. Ap&#243;s 12h de p&#243;s operat&#243;rio, o paciente apresentava press&#227;o arterial m&#233;dia de 63mmHg com uso de dobutamina 10mcg/kg/min, adrenalina 0,96 mcg/kg/min, isoproterenol 0,13 mcg/kg/min e noradrenalina 0,41mcg/kg/min, em franca piora cl&#237;nica com um quadro de hipertens&#227;o pulmonar associado &#224; vasoplegia. O uso de vasoconstritores para a vasoplegia (resist&#234;ncia vascular sist&#234;mica = 238 D.s/cm<sup>5</sup>) era dif&#237;cil pela hipertens&#227;o pulmonar. </p>
    <p>Evoluindo com piora hemodin&#226;mica e olig&#250;ria foi administrado sildenafil 150mg via sonda nasog&#225;strica (16:30 de 03/08/03). A resist&#234;ncia vascular pulmonar diminuiu significativamente (<xref ref-type="table" rid="tab01">tab. I</xref>) e permitiu o uso de maiores doses de vasoconstritores (noradrenalina) para tratamento da vasoplegia, obtendo-se uma resist&#234;ncia vascular sist&#234;mica de 86 D.s/cm<sup>5</sup> (1.08 Wood) com uma resist&#234;ncia vascular sist&#234;mica de 762 D.s/cm<sup>5</sup>. O sildenafil foi mantido em 50mg a cada 8 h e permitiu, no dia seguinte, uma queda importante da press&#227;o arterial pulmonar e na PVC, sem hipertens&#227;o pulmonar mesmo com o uso de noradrenalina. </p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-84-02-0176-00017-gt01.jpg"/></table-wrap>
    <p>Os ecocardiogramas do p&#243;s-operat&#243;rio imediato e do 3&#186; dia p&#243;s-operat&#243;rio mostraram d&#233;ficit importante de ventr&#237;culo direito. Entretanto, medidas hemodin&#226;micas mostravam melhora no desempenho do ventr&#237;culo direito e queda sustentada de resist&#234;ncia vascular pulmonar. A retirada de drogas vasoativas foi progressiva e o ecocardiograma do 6&#186; p&#243;s-operat&#243;rio mostrou d&#233;ficit leve de ventr&#237;culo direito. O paciente teve alta da UTI no 8&#186; p&#243;s-operat&#243;rio, sendo mantido o uso de sildenafil at&#233; o 15&#186; p&#243;s-operat&#243;rio. O ecocardiograma do 17&#186; p&#243;s-operat&#243;rio mostrou fun&#231;&#227;o biventricular preservada, insufici&#234;ncia tric&#250;spide leve e press&#227;o arteiral pulmonar de 45mmHg. O esquema imunossupressor utilizado foi prednisona, micofenolato mofetil e ciclosporina e as bi&#243;psias endomioc&#225;rdicas at&#233; o momento n&#227;o apresentam sinais de rejei&#231;&#227;o. </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>O paciente estudado apresentava hipertens&#227;o pulmonar no pr&#233;-operat&#243;rio (PAPS=52mmHg) mesmo em uso de dobutamina. Apesar do curto tempo de isquemia (117min), houve uma disfun&#231;&#227;o de ventr&#237;culo direito severa, atribu&#237;da &#224; hipertens&#227;o pulmonar. A sobreposi&#231;&#227;o de vasoplegia, seja secund&#225;ria &#224; circula&#231;&#227;o extracorporea ou ao uso de vasodilatadores (dobutamina, isoproterenol, milrinona), tornou dif&#237;cil o manejo do paciente, uma vez que o aumento da dose de vasoconstritores piorava a hipertens&#227;o pulmonar. </p>
    <p>O uso de sildenafil promoveu vasodilata&#231;&#227;o pulmonar importante sem causar vasodilata&#231;&#227;o sist&#234;mica. Pelo seu efeito vasodilatador pulmonar espec&#237;fico, tornou-se poss&#237;vel o uso de vasoconstritores em altas doses (noradrenalina e adrenalina) para tratamento da vasoplegia sem causar vasoconstri&#231;&#227;o pulmonar. Houve retirada das catecolaminas e recupera&#231;&#227;o funcional do ventr&#237;culo direito, demonstrada por ecocardiograma seriado. </p>
    <p>Pacientes candidatos a transplante card&#237;aco em que n&#227;o se obt&#233;m uma resist&#234;ncia vascular pulmonar menor que 2,5 unidades Wood com vasodilatador sem hipotens&#227;o sist&#234;mica ou com press&#227;o de art&#233;ria pulmonar (PAP) elevada (&gt;50mmHg) t&#234;m importante aumento na mortalidade precoce por fal&#234;ncia de enxerto no per&#237;odo p&#243;stransplante<sup>14,15</sup>. A fal&#234;ncia de enxerto &#233; causa de 38,7% dos &#243;bitos nos primeiros 30 dias p&#243;s-transplante<sup>13</sup>. </p>
    <p>Mychaskiw e cols.<sup>9</sup> obtiveram melhora hemodin&#226;mica surpreendente em um paciente com dispositivo de assist&#234;ncia ventricular esquerda e direita em espera de transplante card&#237;aco, que apresentava franca piora hemodin&#226;mica, por uma crise de hipertens&#227;o pulmonar, 20min ap&#243;s o uso de 50mg de sildenafil. Conseguiu interrup&#231;&#227;o do tratamento com &#243;xido n&#237;trico e catecolaminas, e extuba&#231;&#227;o do paciente que parecia ter uma piora cl&#237;nica irrevers&#237;vel. </p>
    <p>O sildenafil &#233; rapidamente absorvido pelo trato gastrointestinal, mesmo de pacientes criticamente enfermos<sup>6</sup>. Altas doses (400mg, quatro vezes ao dia) de sildenafil s&#227;o bem toleradas com poucos efeitos colaterais importantes (hipotens&#227;o, cefal&#233;ia importante)<sup>11</sup>. </p>
    <p>Desta forma, acreditamos que o sildenafil possa ser adequado em pacientes em p&#243;s-operat&#243;rio de transplante card&#237;aco que apresentem disfun&#231;&#227;o ventricular direita importante e mesmo em paciente em condi&#231;&#245;es cr&#237;ticas, uma vez que a droga &#233; absorvida adequadamente, mesmo em m&#225;s condi&#231;&#245;es cl&#237;nicas.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold>Endere&#231;o para correspond&#234;ncia</bold>
        </label>
        <p> Rodrigo Pereira Paez </p>
        <p> Rua Napole&#227;o de Barros, 715 - 3&#186; - Cirurgia Card&#237;aca </p>
        <p> Cep 04082-006 - S&#227;o Paulo - SP </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="rppaez@yahoo.com.br">rppaez@yahoo.com.br</email>
        </p>
      </fn>
    </p>
    <p>Recebido em 08/11/2003 </p>
    <p> Aceito em 17/03/2004</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Schmidt HH, Lohmann SM, Walter U. The nitric    oxide and cGMP signal transduction system: Regulation and mechanism of action.    Biochim Biophys Acta 1993; 7:328-38. </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The nitric oxide and cGMP signal transduction system: Regulation and mechanism of action</article-title>
          <source>Biochim Biophys Acta</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>328</fpage>
          <lpage>38</lpage>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schmidt</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Lohmann</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Walter</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Ichinose F, Adrif C, Hurford WE, et al. Prolonged    pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs.    J Appl Physiol 1995; 78:1288-95. </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs</article-title>
          <source>J Appl Physiol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>1288</fpage>
          <lpage>95</lpage>
          <volume>78</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ichinose</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Adrif</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hurford</surname>
              <given-names>WE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Kinsella JP, Torielli F, Ziegler JW, et al.    Dipyridamol augmentation of response to nitric oxide. Lancet 1995; 346:647-8.    </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Dipyridamol augmentation of response to nitric oxide</article-title>
          <source>Lancet</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>647</fpage>
          <lpage>8</lpage>
          <volume>346</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kinsella</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Torielli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ziegler</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Ziegler JW, Ivy DD, Wiggins JW, et al. Effects    of dipyridamol and inhaled nitric oxide in pediatric patients with pulmonary    hypertension. Am J Respir Crit Care Med 1998; 158:1388-1395. </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of dipyridamol and inhaled nitric oxide in pediatric patients with pulmonary hypertension</article-title>
          <source>Am J Respir Crit Care Med</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1388</fpage>
          <lpage>1395</lpage>
          <volume>158</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ziegler</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Ivy</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Wiggins</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Atz AM, Wessel DL. Sildenafil ameliorates    effects oh inhaled oxide withdrawal. Anesthesiology 1999; 91 (1):307-310. </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sildenafil ameliorates effects oh inhaled oxide withdrawal</article-title>
          <source>Anesthesiology</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>307</fpage>
          <lpage>310</lpage>
          <issue>1</issue>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Atz</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Wessel</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Bigatello LM, Hess D, Dennehy KC, et al. Sildenafil    can increase the response to inhaled nitric oxide. Anesthesiology 2000; 92:1827-1829.    </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sildenafil can increase the response to inhaled nitric oxide</article-title>
          <source>Anesthesiology</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1827</fpage>
          <lpage>1829</lpage>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bigatello</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Hess</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Dennehy</surname>
              <given-names>KC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Atz AM, Lefler AK, Fairbrother DL, et al.    Sildenafil augments the effect of inhaled oxide for postoperative pulmonary    crises. J Thorac Cardiovas Surg 2002; 124:628-9. </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sildenafil augments the effect of inhaled oxide for postoperative pulmonary crises</article-title>
          <source>J Thorac Cardiovas Surg</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>628</fpage>
          <lpage>9</lpage>
          <volume>124</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Atz</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Lefler</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Fairbrother</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Lepore JL, Maroo A, Pereira NL, et al. Effect    of sidenafil on the acute pulmonary vasodilator response to inhaled nitric oxide    in adults with primary pulmonary hypertension. Am J Cardiol 2002; 90:677-680.    </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of sidenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>677</fpage>
          <lpage>680</lpage>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lepore</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Maroo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>NL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Mychaskiw G, Sachdev V, Heath BJ. Sildenafil    (Viagra) facilitates weaning of inha led nitric oxide following placement of    a biventricular- assist device. J Clin Anesth 2001;13:218-220. </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sildenafil (Viagra) facilitates weaning of inha led nitric oxide following placement of a biventricular- assist device</article-title>
          <source>J Clin Anesth</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>218</fpage>
          <lpage>220</lpage>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mychaskiw</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sachdev</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Heath</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Weimann J, Ullrich R, Hromi J, et al. Sildenafil    is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.    Anesthesiology 2000;92:1702-12. </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension</article-title>
          <source>Anesthesiology</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1702</fpage>
          <lpage>12</lpage>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Weimann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ullrich</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hromi</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Molina J, Luluaga S, Bellomio V, et al. Systemic    lupus erytematosus-associated pulmonary mypertension: good outcome following    sildenafil therapy. Lupus 2003;12:321-323. </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Systemic lupus erytematosus-associated pulmonary mypertension: good outcome following sildenafil therapy</article-title>
          <source>Lupus</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>321</fpage>
          <lpage>323</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Molina</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Luluaga</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bellomio</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Michelakis E, Tymchak W, Lien D, et al. Oral    sildenafil is an effective and specific pulmonary vasodilator in patients with    pulmonary arterial hypertension. Circulation 2002;105:2398-2403. </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>2398</fpage>
          <lpage>2403</lpage>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Michelakis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tymchak</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Lien</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Taylor DO, Edwards LB, Mohacsi PJ, et al.    The registry of the international society for heart and lung transplantation:    Twentieth official adult heart transplant report - 2003. J Heart Lung Transplant    2003; 22:610-672. </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The registry of the international society for heart and lung transplantation: Twentieth official adult heart transplant report - 2003</article-title>
          <source>J Heart Lung Transplant</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>610</fpage>
          <lpage>672</lpage>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Mohacsi</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Costcard-Jackle A, Schroeder JS, Folwer MB.    The influence of preoperative patient characteristics on early an d late survival    following cardiac transplantation. Circulation 1991; 84 (suppl 3): III-329-III-337.    </mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The influence of preoperative patient characteristics on early an d late survival following cardiac transplantation</article-title>
          <source>Circulation</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>III</fpage>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Costcard-Jackle</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schroeder</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Folwer</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Chen JM, Michler RE. The problem of pulmonary    hypertension in the potential cardiac transplant recipient. <italic>In</italic> Cooper    D, Miller L, Patterson G (eds): The transplantation and replacement oh thoracic    organs. Lancaster: Kluwer Academic Publisher, 1996, pp177-183.</mixed-citation>
        <element-citation publication-type="book">
          <source>The transplantation and replacement oh thoracic organs</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>pp177</fpage>
          <lpage>183</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Michler</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Patterson</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Sildenafil improves right ventricular function in a cardiac transplant recipient</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>We report the case of a male patient who underwent orthotopic cardiac transplantation. A marginal donor was used, because the recipient's clinical condition was critical. He experienced cardiogenic shock due to right ventricular dysfunction secondary to pulmonary hypertension associated with vasoplegia. After the introduction of sildenafil, the patient recovered hemodynamically, his pulmonary vascular resistance decreased, the vasoactive drugs were withdrawn, and his right ventricular function improved.</p>
      </abstract>
    </front-stub>
    <body>
      <p>
        <bold>CASE REPORT</bold>
      </p>
      <p>Sildenafil improves right ventricular function in a cardiac transplant recipient</p>
      <p>Rodrigo Pereira Paez; Wesley Ferreira Araujo; Nelson Americo Hossne Jr; Ana Lucia Neves; Guilherme Flora Vargas; Luciano de Figueiredo Aguiar; Jo&#227;o Nelson Rodrigues Branco; Roberto Catani; Enio Buffolo</p>
      <p>S&#227;o Paulo, SP - Brazil</p>
      <p>Escola Paulista de Medicina - Universidade Federal de S&#227;o Paulo </p>
      <p>
        <xref ref-type="corresp" rid="end-body2">Correspondence</xref>
      </p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p> We report the case of a male patient who underwent orthotopic cardiac transplantation. A marginal donor was used, because the recipient's clinical condition was critical. He experienced cardiogenic shock due to right ventricular dysfunction secondary to pulmonary hypertension associated with vasoplegia. After the introduction of sildenafil, the patient recovered hemodynamically, his pulmonary vascular resistance decreased, the vasoactive drugs were withdrawn, and his right ventricular function improved. </p>
      <p>The use of inhaled nitric oxide reduces pulmonary artery pressure, increasing the production of guanosine 3',5'-cyclic monophosphate (GMPc) in the smooth muscle cells of the lung <sup>1</sup>. Specific inhibitors of GMPc phosphodiesterase (PDE5), which hydrolyzes GMPc in vascular smooth muscle, cause pulmonary vasodilation <sup>2-4</sup>. </p>
      <p>Sildenafil is a specific inhibitor of PDE5 that increases the pulmonary vasodilating effect of inhaled nitric oxide<sup> 5-8</sup>, prevents pulmonary hypertensive crises after weaning of nitric oxide in patients with severe pulmonary hypertension <sup>5,9</sup>, and has its own pulmonary vasodilating effect <sup>10,11 </sup>by increasing the GMPc levels <sup>12</sup>. </p>
      <p>Molina et al <sup>11</sup> reported a 20% reduction in the PAP of a patient with pulmonary hypertension due to systemic lupus erythematosus, who had suprasystemic pulmonary pressure levels, with elevated doses of sildenafil (1600 mg per day). The authors reported a good tolerance to the medication. </p>
      <p>In an experimental study, Weimann et al <sup>10 </sup>showed that the pulmonary vasodilating effect of sildenafil is dose-dependent, beginning 5 minutes after its administration and reaching its maximum effect in 10 minutes. </p>
      <p>Michelakis et al <sup>12</sup> showed that patients with pulmonary hypertension who are candidates for cardiac transplantation had a decrease in pulmonary vascular resistance that was more prominent with sildenafil alone, at the dosage of 75mg, than with inhaled nitric oxide in 80 ppm, associated with a significant increase in GMPc levels. </p>
      <p>The use of a female donor for a male recipient is known to have a greater early mortality (OR=1.11, P=0.3), similarly to that of a recipient using vasoactive drugs and waiting in the intensive care unit (OR=2.51, P&lt;0.0001)<sup>13-15</sup>. </p>
      <p>We report the case of a patient undergoing orthotopic cardiac transplantation, who experienced cardiogenic shock due to right ventricular dysfunction secondary to pulmonary hypertension associated with vasoplegia. Because the recipient's clinical condition was critical, a marginal donor was used. </p>
      <p>In the national literature, we did not find reports of the use of sildenafil for pulmonary hypertension in the postoperative period. The objective of this report is to propose a new and safe manner to treat right ventricular failure secondary to pulmonary hypertension in the postoperative period of cardiac transplantation. </p>
      <p>
        <bold>Case Report</bold>
      </p>
      <p>The patient was a 33-year-old man with idiopathic dilated cardiomyopathy, who had been in NYHA functional class IV for the preceding 2 years and was hospitalized with low cardiac output and was using catecholamines (dobutamine, 6.6 mcg/kg/min, and dopamine, 8 mcg/kg/min). The patient was hypotensive (blood pressure of 70x40 mmHg), slightly dyspneic at rest, and had hepatomegaly and pulmonary congestion (basal rales in both bases). </p>
      <p>The patient underwent orthotopic cardiac transplantation on 08/02/2003. Due to his rapid clinical worsening, a marginal organ was used. The marginal donor was a 60-kg female, who had experienced cardiac arrest for 15 minutes 3 days before, was using 12 mcg/kg/min of dopamine, and, on the echocardiogram, had diffuse, mild hypokinesia and preserved overall function. </p>
      <p>The transplantation was performed according to the bicaval technique with 165 minutes of extracorporeal circulation and 117 minutes of anoxia, under mild hypothermia (32&#186;C) and use of intermittent anterograde blood cardioplegia. The patient was removed from the extracorporeal circulation after the third attempt and sent to the ICU receiving 0.11 mcg/kg/min of isoproterenol, 0.75 mcg/kg/min milrinone, and 20mcg/kg/min of dobutamine. His mean blood pressure was 40 mmHg and mean pulmonary arterial pressure was 45 mmHg. His right ventricular contractility was very poor, and he received adrenaline in bolus during transportation and in the first hours at the ICU. Twelve hours after transplantation, the patient was receiving 10mcg/kg/min of dobutamine, 0.96 mcg/kg/min of adrenaline, 0.13 mcg/kg/min of isoproterenol, and 0.41 mcg/kg/ min of noradrenaline, and his mean blood pressure was 63 mmHg. His clinical condition was clearly worsening, with pulmonary hypertension associated with vasoplegia. The use of vasoconstrictors for vasoplegia (systemic vascular resistance = 238 D.s/cm<sup>5</sup>) was hindered by pulmonary hypertension. </p>
      <p>As the patient evolved with aggravation of the hemodynamic condition and oliguria, 150 mg of sildenafil was administered through a nasogastric probe (4:30 PM on 08/03/03). The pulmonary vascular resistance significantly decreased (<xref ref-type="table" rid="tab01-body2">tab. I</xref>), allowing the use of greater doses of vasoconstrictors (noradrenaline) for treating vasoplegia, and the following values were obtained: pulmonary vascular resistance of 86 D.s/cm<sup>5</sup> (1.08 Wood) and systemic vascular resistance of 762 D.s/cm<sup>5</sup>. Sildenafil was maintained at the dosage of 50mg every 8 hours, allowing, on the following day, a significant drop in pulmonary arterial pressure and in CVP, without pulmonary hypertension even with the use of noradrenaline. </p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-84-02-0176-00017-gt01-en.jpg"/></table-wrap>
      <p>The echocardiograms in the immediate postoperative period and third postoperative day showed a significant right ventricular deficit. However, the hemodynamic measurements showed an improvement in right ventricular performance and a sustained drop in pulmonary vascular resistance. The suspension of the vasoactive drugs was progressive, and the echocardiogram on the sixth postoperative day showed a mild right ventricular deficit. The patient was discharged from the ICU on the eighth postoperative day, and the use of sildenafil was maintained until the 15th postoperative day. The echocardiogram of the 17th postoperative day showed a preserved biventricular function, mild tricuspid regurgitation, and pulmonary arterial pressure of 45 mmHg. The immunosuppressive scheme used comprised prednisone, mycophenolate mofetil, and cyclosporine. So far, the endomyocardial biopsies have shown no sign of rejection. </p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>The patient studied had preoperative pulmonary hypertension (PAP=52 mmHg) even while using dobutamine. Despite the short period of ischemia (117 minutes), severe right ventricular dys function developed, being attributed to pulmonary hypertension. The overlapping vasoplegia, secondary to either extracorporeal circulation or the use of vasodilators (dobutamine, isoproterenol, milrinone), made the patient's management difficult, because the increase in the doses of vasoconstrictors aggravated pulmonary hypertension. </p>
      <p>The use of sildenafil caused significant pulmonary vasodilation without causing systemic vasodilation. Its specific pulmonary vasodilating effect allowed the use of high doses of vasoconstrictors (noradrenaline and adrenaline) for the treatment of vasoplegia without causing pulmonary vasoconstriction. The catecholamines were suspended and the right ventricular function recovered, which was evident on serial echocardiography. </p>
      <p>Patient candidates for cardiac transplantation, in whom a pulmonary vascular resistance lower than 2.5 Wood units is not obtained with a vasodilator without systemic hypotension or with elevated pulmonary arterial pressure (PAP &gt;50 mmHg), have a significant increase in early mortality due to graft failure after transplantation <sup>14,15</sup>. Graft failure accounts for 38.7% of the deaths in the first 30 days after transplantation <sup>13</sup>. </p>
      <p>Mychaskiw et al <sup>9</sup> reported a surprising hemodynamic improvement in a patient with a device for left and right ventricular support waiting for cardiac transplantation, who was experiencing clear hemodynamic worsening due to a pulmonary hypertension crisis, 20 minutes after receiving 50 mg of sildenafil. The authors managed to interrupt the treatment with nitric oxide and catecholamines, and extubate the patient who seemed to have an irreversible clinical worsening. </p>
      <p>Sildenafil is rapidly absorbed through the gastrointestinal tract, even in critically ill patients <sup>6</sup>. High doses (400 mg, 4 times a day) of sildenafil are well tolerated and have few significant side effects (hypotension, significant cephalea) <sup>11</sup>. </p>
      <p>Therefore, we believe that sildenafil may be adequate for the postoperative period of patients undergoing cardiac transplantation, who have significant right ventricular dysfunction, and even in patients in critical condition, as long as the drug is adequately absorbed, even in poor clinical conditions.</p>
      <p>
        <bold>References</bold>
      </p>
      <p>
        <fn id="end-body2" fn-type="corresp">
          <label>
            <bold>Correspondence to</bold>
          </label>
          <p> Rodrigo Pereira Paez</p>
          <p> Rua Napole&#227;o de Barros, 715</p>
          <p> 3&#186; - Cirurgia Card&#237;aca</p>
          <p> Cep 04082-006 - S&#227;o Paulo, SP, Brazil</p>
          <p> E-mail: </p>
          <p>
            <email xlink:href="rppaez@yahoo.com.br">rppaez@yahoo.com.br</email>
          </p>
        </fn>
      </p>
      <p>Received for publication: 11/08/2003</p>
      <p> Accepted for publication: 03/17/2004</p>
      <p> English version by Stela Maris Costalonga</p>
    </body>
  </sub-article>
</article>
